The companies also said the latest analysis of the Israeli data shows the vaccine was 97 percent effective in preventing symptomatic disease, severe disease and death. That is basically in line with the 95 percent efficacy Pfizer and BioNTech reported from the vaccine’s late-stage clinical trial in December.
According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from Covid-19 than those who had received the vaccine.
The data, collected between Jan. 17 and March 6, has not yet been peer reviewed.
Israel’s Health Ministry previously found the Pfizer vaccine developed with Germany’s BioNTech reduces infection, including in asymptomatic cases, by 89.4 percent and in syptomatic cases by 93.7 percent. That was in data collected between Jan. 17 and Feb. 6.